In 2026, the Beijing Financial Court and the High People's Court of Beijing Municipality("Beijing High People's Court")ruled that Chinese mainland courts had jurisdiction over securities fraud involving a Cayman Islands company listed on the Hong Kong Stock Exchange (HKEX). This landmark decision sets a precedent as the first instance in which judicial authorities in Chinese mainland applied the Securities Law of the PRC (the "Securities Law") extraterritorially. The decision is recognized as a "typical case" and has been included in theReport on the Work of the Supreme People's Court (2026)[1]...
Han Kun Law Offices
Offices
Overview
Han Kun is a leading full-service law firm in China. Over the years, Han Kun has been widely recognized as a leader in complex cross-border and domestic transactions and compliance matters.
Our main practice areas include private equity, mergers and acquisitions, international and domestic capital markets, investment funds, asset management, compliance, banking and finance, aviation finance, foreign direct investment, antitrust/competition, data protection, private client/wealth management, intellectual property, bankruptcy and restructuring and dispute resolution.
We have more than 900 professionals located in Beijing, Shanghai, Shenzhen, Hangzhou, Wuhan, Haikou, Hong Kong, Singapore, New York, Silicon Valley and London.
All our lawyers are graduates of top universities and have extensive experience in complex cross-border transactions and dispute resolution as counsel to both Chinese and foreign clients.
Our working languages include Chinese, English, Japanese, Korean and German.
Areas of Practice
Professionals
Articles
China's HGR Draft Rules Signal Regulatory Easing: Key Takeaways from the Implementing Rules for the Administrative Regulation on Human Genetic Resources (Draft for Comments)
On May 8, 2026, the National Health Commission ("NHC") released theImplementing Rules for the Administrative Regulation on Human Genetic Resources (Draft for Comments)("Draft for Comments"), proposing amendments to the currentImplementing Rules for the Administrative Regulation on Human Genetic Resources("Current Implementing Rules") formulated by the Ministry of Science and Technology ("MOST") in 2023 (for our interpretation of the Current Implementing Rules, please see our previous article:Han Kun Perspective First Release: Key Takeaways from the Implementing Rules for the Administrative Regulation on Human Genetic Resources), and is soliciting public comments...
Press releases
Han Kun Advises Everest Medicines in Acquiring an Exclusive License with Vcare PharmaTech for Sumecigrel, a P2Y12 receptor antagonist, in Asia-Pacific Markets
On June 9, 2026, Everest Medicines (HKEX: 1952) announced that it had entered into an agreement with Jiangsu Vcare PharmaTech Co., Ltd. ("Vcare PharmaTech"), under which Everest Medicines obtained the exclusive rights to develop, register and commercialize Sumecigrel (formerly known as Vicagrel), a P2Y12 receptor antagonist, in multiple countries and regions across Asia-Pacific, including Southeast Asia, South Korea, Australia, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan region, China...
Han Kun again recognized in MIP's IP STARS rankings
Managing Intellectual Property (MIP), a world-renowned IP publication, has recently announced its 2026 global IP STARS rankings. Han Kun was again recognized in the China domestic firm categories of "IP transactions (Tier 1)", "Patent disputes", "Trademark disputes", "Patent prosecution", and "Copyright", owing to the firm's competitive IP division and exceptional service capabilities. This is the sixth consecutive year for Han Kun to appear in the rankings, which reflects MIP's affirmation of the firm's comprehensive strength and influence.Besides these firm-level accolades, Han Kun partners Lili Wu and Yan Wang were recognized as "IP Stars" again...